Informatics of drug synergism in naturally occurring anticancer agents

Autor: Ghazaleh Ghavami, Soroush Sardari, Mohammad Reza Kazemali
Přispěvatelé: Drug Design and Bioinformatics Unit, Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Biotechnology Research Center, Ghazaleh Ghavami, Mohammad R. Kazemali, Soroush Sardari
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Cancer Research
MESH: Informatics
Informatics
Drug resistance
Disease
Pharmacology
MESH: Drug Synergism
0302 clinical medicine
Neoplasms
Drug Discovery
Antineoplastic Combined Chemotherapy Protocols
Pharmacology (medical)
MESH: Neoplasms
media_common
Cancer
0303 health sciences
cheminformatics
MESH: Biological Agents
Drug Synergism
General Medicine
bioinformatics
Effective dose (pharmacology)
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Oncology
Cheminformatics
030220 oncology & carcinogenesis
Algorithms
MESH: Computational Biology
Drug
Drug Industry
media_common.quotation_subject
Antineoplastic Agents
MESH: Algorithms
Patents as Topic
03 medical and health sciences
Pharmacotherapy
synergism
medicine
Humans
MESH: Patents as Topic
030304 developmental biology
Biological Products
drug resistance
MESH: Humans
business.industry
Computational Biology
medicine.disease
MESH: Drug Industry
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
MESH: Antineoplastic Agents
business
Zdroj: Recent Patents on Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery, Bentham Science Publishers, 2011, 6 (1), pp.26-44. ⟨10.2174/157489211793980105⟩
ResearcherID
ISSN: 1574-8928
2212-3970
DOI: 10.2174/157489211793980105⟩
Popis: International audience; Cancer is a multi-factorial disease resulting in uncontrolled division of body cells, with difficult and complex suppression. The main treatment strategy for this disease depends on killing of tumor cells that usually exist in the proximity of normal body cells. During the course of treatment, the healthy cells should not be affected by the toxic doses of the drug. Therefore, it seems that combination drug therapy is a suitable solution to address the mentioned concern. Indeed the use of multiple drugs with different actions and/or targets, in order to overcome the tumor cells, can lead to decreased drug effective dose and increased protection of normal cells against antitumor drugs. This review is focused on informatics applications in cancer combination drug therapy. At first, a brief description of recent findings on biology of resistance to cytotoxic agents is covered. Then, combinational drug therapy in cancer treatment, cheminformatics applications of synergistic compounds in cancer therapy, strategies used to overcome MDR (Multi Drug Resistance) and combinational drug therapy in cancer treatment have been discussed in the continuation. Natural compounds synergistic with anticancer agents have been reviewed in the following topics and lastly, the recent patents in the related area of combinational therapy are briefed.
Databáze: OpenAIRE
Externí odkaz: